Earnings Releases·Nov 12, 2026, 4:15 PM ET

VolitionRx Limited — Third Quarter 2026 Earnings Summary

Revenue surged 157% year-over-year to $1.6 million driven by deferred revenue recognition, while operating expenses fell 14% due to a cost-reduction program that cut headcount by 28%.
Operating loss narrowed 35% to $3.3 million and net loss decreased to $3.8 million; cash reserves increased to $2.4 million following $5.2 million in net proceeds from an at-the-market facility and the cash prepayment of a $7.5 million convertible note.
Strategic progress includes a French government-funded €6.3 million sepsis program launch for Nu.Q® NETs, active licensing discussions for Nu.Q® Cancer targeting over $36 billion in addressable markets, and a pending clinical manuscript for Nu.Q® Vet required to unlock a $5 million milestone.
Management executed significant cost-cutting measures, including a 50% voluntary salary reduction by the CEO and a 50% fee reduction by the board, effective November 1, 2026, until a substantial licensing agreement is executed.